<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41552868</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-1753</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of dermatological treatment</Title><ISOAbbreviation>J Dermatolog Treat</ISOAbbreviation></Journal><ArticleTitle>Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies.</ArticleTitle><Pagination><StartPage>2612873</StartPage><MedlinePgn>2612873</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09546634.2026.2612873</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="UNASSIGNED">Given the chronic nature of acne, two 6-month studies were conducted to evaluate the long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB)-the only approved triple-combination acne topical-and its effects on scarring/dyspigmentation in participants with moderate to severe acne.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">Data were pooled from 2 identical, open-label, single-center studies conducted in participants (<i>N</i>&#x2009;=&#x2009;50) aged &#x2265;12&#x2009;years with Investigator's Global Assessment (IGA) score of 3/4. Endpoints included change from baseline in IGA score, inflammatory/noninflammatory lesions, skin appearance (dryness, postinflammatory hyperpigmentation [PIH], postinflammatory erythema [PIE]), and scarring. Adverse events and tolerability (itching, burning, redness, swelling) were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (<i>p</i>&#x2009;&lt;&#x2009;0.001, both). Significant reductions in scarring (33%), investigator- and participant-assessed PIH (71%; 78%, respectively), and PIE (77%; 77%, respectively) were demonstrated (<i>p</i>&#x2009;&lt;&#x2009;0.001, all). Most participants (&gt;70%) reported no tolerability issues throughout the studies. Seven adverse events occurred; 4 were related to CAB, and 3 led to study discontinuation (BPO allergy [<i>n</i>&#x2009;=&#x2009;2], irritant contact dermatitis to BPO [<i>n</i>&#x2009;=&#x2009;1]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">These findings suggest that CAB is an appropriate and effective topical option for the long-term treatment of acne vulgaris.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Draelos</LastName><ForeName>Zoe D</ForeName><Initials>ZD</Initials><AffiliationInfo><Affiliation>Dermatology Consulting Services, High Point, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Hilary</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Acne Treatment and Research Center, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harper</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Dermatology &amp; Skin Care Center of Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghannoum</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Linda Stein</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanghetti</LastName><ForeName>Emil A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Center for Dermatology and Laser Surgery, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wroblewski</LastName><ForeName>Karol</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice and Administration, Rutgers University, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kircik</LastName><ForeName>Leon H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physicians Skin Care, DermResearch, and Skin Sciences, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Dermatolog Treat</MedlineTA><NlmUniqueID>8918133</NlmUniqueID><ISSNLinking>0954-6634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3U02EL437C</RegistryNumber><NameOfSubstance UI="D002981">Clindamycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003879">Dermatologic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005782">Gels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000068801">Adapalene, Benzoyl Peroxide Drug Combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>W9WZN9A0GM</RegistryNumber><NameOfSubstance UI="D001585">Benzoyl Peroxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EH6D7113I8</RegistryNumber><NameOfSubstance UI="C007084">clindamycin phosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000152" MajorTopicYN="Y">Acne Vulgaris</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002981" MajorTopicYN="Y">Clindamycin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003879" MajorTopicYN="Y">Dermatologic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068801" MajorTopicYN="Y">Adapalene, Benzoyl Peroxide Drug Combination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001585" MajorTopicYN="Y">Benzoyl Peroxide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002921" MajorTopicYN="N">Cicatrix</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Combination treatment</Keyword><Keyword MajorTopicYN="N">antibiotic</Keyword><Keyword MajorTopicYN="N">antimicrobial</Keyword><Keyword MajorTopicYN="N">hyperpigmentation</Keyword><Keyword MajorTopicYN="N">long-term treatment</Keyword><Keyword MajorTopicYN="N">retinoid</Keyword><Keyword MajorTopicYN="N">scarring</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>12</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41552868</ArticleId><ArticleId IdType="doi">10.1080/09546634.2026.2612873</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41416232</PMID><DateCompleted><Year>2025</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1941-2789</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of clinical and aesthetic dermatology</Title><ISOAbbreviation>J Clin Aesthet Dermatol</ISOAbbreviation></Journal><ArticleTitle>Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% to Treat Acne Induced by Janus Kinase Inhibitor Treatment: A Case Report.</ArticleTitle><Pagination><StartPage>36</StartPage><EndPage>39</EndPage><MedlinePgn>36-39</MedlinePgn></Pagination><Abstract><AbstractText>Janus kinase inhibitors (JAKi)-developed to treat inflammatory and immune-mediated diseases-have shown an increased risk of acne development, especially when used to treat dermatologic conditions. There are no treatment guidelines for JAKi-induced acne. Some of the most efficacious treatments for acne vulgaris (AV) are triple combinations, including benzoyl peroxide (BPO), a topical retinoid, and an oral/topical antibiotic. Fixed-dose, triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% (CAB) gel has demonstrated good efficacy, safety, and tolerability in Phase 2 and 3 clinical trials of participants with moderate to severe AV. This case report highlights the possible utility of once-daily CAB for JAKi-induced acne. A 15-year-old female patient was administered the oral JAKi upadacitinib (15mg daily) for 16 weeks to treat atopic dermatitis that inadequately responded to dupilumab. The patient had mild preexisting comedonal and inflammatory facial AV prior to JAKi treatment. Over the first few months of JAKi treatment, her acne worsened to moderate/severe inflammatory acne, with erythema and postinflammatory hyperpigmentation. The patient applied CAB gel to the face once daily for approximately 20 weeks with substantial acne improvement and without adverse effects. CAB treatment reduced her acne severity to mild to almost clear, and no significant acne-induced sequelae (scarring, postinflammatory hyperpigmentation, or erythema) were observed. She continues treatment with both CAB and upadacitinib. Treatment guidelines for AV often recommend oral drugs, such as isotretinoin, for moderate-to-severe acne. This case presented here, however, demonstrates that topical CAB gel can treat moderate to severe JAKi-induced inflammatory acne.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Matrix Medical Communications. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olszewski</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Ms. Olszewski is with the Yale Center for Clinical Investigation at the Yale School of Medicine in New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunick</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Dr. Bunick is with the Department of Dermatology and Program in Translational Biomedicine at the Yale School of Medicine in New Haven, Connecticut.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Aesthet Dermatol</MedlineTA><NlmUniqueID>101518173</NlmUniqueID><ISSNLinking>1941-2789</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Janus kinase inhibitor</Keyword><Keyword MajorTopicYN="N">acne</Keyword><Keyword MajorTopicYN="N">antibiotic</Keyword><Keyword MajorTopicYN="N">benzoyl peroxide</Keyword><Keyword MajorTopicYN="N">fixed-dose</Keyword><Keyword MajorTopicYN="N">retinoid</Keyword><Keyword MajorTopicYN="N">topical</Keyword></KeywordList><CoiStatement>DISCLOSURES: Ms. Olszewski served as a Clinical Research Coordinator for AbbVie&#x2019;s LEVEL-UP clinical trial. Dr. Bunick has served as an investigator and/or consultant for AbbVie, Almirall, Amgen, Apogee, Arcutis, Botanix, Connect BioPharma, Daiichi Sankyo, Dermavant, Eli Lilly, EPI Health/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Timber, Teladoc, and UCB.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41416232</ArticleId><ArticleId IdType="pmc">PMC12710872</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballanger F, Auffret N, Leccia MT et al. Acneiform lesions but not acne after treatment with Janus kinase inhibitors: diagnosis and management of Janus kinase-acne. Acta Derm Venereol. 2023;103</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10296536</ArticleId><ArticleId IdType="pubmed">37345975</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia C, Antunes J, Filipe P. Management of acne induced by JAK inhibitors. Dermatol Ther. 2022;35</Citation><ArticleIdList><ArticleId IdType="pubmed">35789037</ArticleId></ArticleIdList></Reference><Reference><Citation>Shawky AM, Almalki FA, Abdalla AN et al. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146299</ArticleId><ArticleId IdType="pubmed">35631587</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J, Manjaly C, Manjaly P et al. Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023;159:1339&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10585588</ArticleId><ArticleId IdType="pubmed">37851459</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen BL, Huang S, Dong XW et al. Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis. J Dermatolog Treat. 2024;35:2397477.</Citation><ArticleIdList><ArticleId IdType="pubmed">39218446</ArticleId></ArticleIdList></Reference><Reference><Citation>Avallone G, Mastorino L, Tavoletti G et al. Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: a multicenter retrospective study. J Am Acad Dermatol. 2024;90:1031&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">38199282</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds RV, Yeung H, Cheng CE et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90:1006.e1001&#x2013;1006.e1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">38300170</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CY, Chang IJ, Bolick N et al. Comparative efficacy of pharmacological treatments for acne vulgaris: a network meta-analysis of 221 randomized controlled trials. Ann Fam Med. 2023;21:358&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10365865</ArticleId><ArticleId IdType="pubmed">37487721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortho Dermatologics. Bridgewater, NJ: Ortho Dermatologics; 2023. Cabtreo&#xae;. Clindamycin phosphate, adapalene, and benzoyl peroxide gel.</Citation></Reference><Reference><Citation>Stein Gold L, Baldwin H, Kircik LH et al. Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase II study of the first triple-combination drug. Am J Clin Dermatol. 2022;23:93&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776677</ArticleId><ArticleId IdType="pubmed">34674160</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein Gold L, Lain E, Del Rosso JQ et al. Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: efficacy and safety results from two randomized phase 3 trials. J Am Acad Dermatol. 2023;89:927&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">37656094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lain ET, Bhatia N, Kircik L et al. Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for male and female acne: phase 3 analysis. J Drugs Dermatol. 2024;23:873&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">39361705</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin H, Gold LS, Harper JC et al. Triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne in adult and pediatric participants. J Drugs Dermatol. 2024;23:394&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">38834226</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichenfield LF, Hebert AA, Harper JC et al. Triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne in children and adolescents. J Drugs Dermatol. 2024;23:1049&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">39630680</ArticleId></ArticleIdList></Reference><Reference><Citation>Callender V, Alexis A, Bhatia N et al. Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Black participants with moderate to severe acne. J Clin Aesthet Dermatol. 2025;18:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12007653</ArticleId><ArticleId IdType="pubmed">40256338</ArticleId></ArticleIdList></Reference><Reference><Citation>Callender VD, Baldwin H, Gold LS et al. Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis. J Dermatolog Treat. 2025;36:2480232.</Citation><ArticleIdList><ArticleId IdType="pubmed">40122140</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverberg JI, Bunick CG, Hong HC et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). Br J Dermatol. 2024;192:36&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">39438067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayslich C, Grange PA, Dupin N. Cutibacterium acnes as an opportunistic pathogen: an update of Its virulence-associated factors. Microorganisms. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7913060</ArticleId><ArticleId IdType="pubmed">33540667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurokawa I, Layton AM, Ogawa R. Updated treatment for acne: targeted therapy based on pathogenesis. Dermatol Ther (Heidelb). 2021;11:1129&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8322376</ArticleId><ArticleId IdType="pubmed">34115308</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad SM, Tawfik YM, El-Mokhtar MA et al. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther. 2021;34:e14563.</Citation><ArticleIdList><ArticleId IdType="pubmed">33210790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-E, Jang Y, Shin K-O, Lee SE. JAK inhibitors increase sebum production in human sebocytes and facial skin of patients with atopic dermatitis: implications for JAK inhibitor-induced acne.. Presented at: Society for Investigative Dermatology; May 7-10, 2025; San Diego, CA..</Citation></Reference><Reference><Citation>Thyssen JP, Nymand LK, Maul JT et al. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022;36:890&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">35220619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>